5-campestenone

5-Campestenone (Campest-5-en-3-one)

1. Identity

1.1 Chemical Names and Nomenclature

5-Campestenone is most formally designated by the systematic IUPAC-derived name campest-5-en-3-one, and is also known by the semi-systematic name 24-methylcholest-5-en-3-one. It is an enone derivative of campesterol. The compound belongs to the broader chemical class of 3-oxo sterols (also called stenones or ketosterols): phytosterol molecules in which the 3β-hydroxyl group characteristic of the parent sterol has been oxidized to a ketone, and a conjugated Δ5 double bond is retained in the B-ring. The signal at C-3 (δC 199.9) is characteristic of a 3-ketosteroid structure, and the olefinic hydrogen H-4 in a steroidal nucleus indicates the conjugated carbonyl arrangement.

5-Campestenone is a chemical modification product of the naturally-occurring plant sterol campesterol. The molecular formula of the parent sterol campesterol is C₂₈H₄₈O; oxidation of the 3β-hydroxyl to a ketone yields 5-campestenone with molecular formula C₂₈H₄₆O and a molecular weight of approximately 398.67 g/mol. The compound is closely related structurally to the analogous cholesterol-derived ketone, cholest-5-en-3-one (5-cholestenone), differing only in the presence of a 24α-methyl substituent on the side chain inherited from campesterol. Several 3-oxo derivatives of cholesterol and phytosterols — including cholest-4-en-3-one (4-cholestenone) and campest-5-en-3-one (5-campestenone) — have been investigated for anti-obesity and lipid-lowering effects.

1.2 Natural Source and Relationship to Campesterol

Campesterol, the direct precursor of 5-campestenone, is a phytosterol whose chemical structure is similar to that of cholesterol; many vegetables, fruits, nuts, and seeds contain campesterol, but in low concentrations. Banana, pomegranate, pepper, coffee, grapefruit, cucumber, onion, oat, potato, and lemon grass are examples of common sources containing campesterol at roughly 1–7 mg/100 g of the edible portion; canola and corn oils contain as much as 16–100 mg/100 g. Beta-sitosterol, campesterol, and stigmasterol are the most common plant-derived sterols in the human diet.

5-Campestenone itself arises from campesterol through oxidative loss of the 3β-hydroxyl group. Oxysterols — oxidized derivatives of cholesterol and phytosterols — can be generated in the human organism through different oxidation processes, some requiring enzymes; they are also present in food due to lipid oxidation reactions caused by heating treatments, contact with oxygen, and exposure to sunlight, and they can be absorbed from the diet at different rates depending on their side chain length. In plants, 5-campestenone occupies a specific enzymatic role as an intermediate in the biosynthesis of brassinosteroids. The enzyme DET2 catalyzes the 5α-reduction of campestenone to 5α-campestanone, and DET2 shares a consistent grade of similarity with mammalian 5α-reductase, which is involved in the production of dihydrotestosterone from testosterone. Complete, parallel biosynthetic pathways of brassinosteroids originating with the C28 phytosterol campesterol were elucidated; following the three-step reduction of campesterol to campestanol, which involves (24R)-ergost-4-en-3-one and (24R)-5α-ergostan-3-one intermediates, biosynthesis of castasterone and brassinolide can proceed by either of two routes.

5-Campestenone can also be detected as a food-processing byproduct. Due to their chemical structure, phytosterols are susceptible to oxidation under certain conditions, giving rise to a family of compounds known as phytosterol oxidation products (POPs). Autoxidation of phytosterols can take place not only in the body but also in foods during food storage and especially during heating processes such as cooking, frying, and baking, leading to the formation of POPs in foods. In meat, POPs were undetectable before frying; however, their concentration range was 0.1–1.6 µg/g after frying as a result of phytosterol oxidation in oil during the cooking process, and only epoxy and keto derivatives of campesterol and sitosterol were identified.

1.3 Common Forms and Preparations

5-Campestenone does not exist as a recognized, widely commercialized standalone dietary supplement ingredient at this time. In research contexts it is obtained principally through chemical synthesis rather than direct extraction from plant material. Campest-5-en-3-one was chemically synthesized from campesterol according to the method of Parish et al. This approach begins with highly purified campesterol as starting material, which is then subjected to selective oxidation of the 3β-hydroxyl group. In experimental studies, the compound has been administered to animals as a dietary admixture — blended directly into powdered chow at defined weight-per-weight percentages. As a phytosterol oxidation product (POP), trace amounts of 5-campestenone and its structural relatives can form naturally in processed foods that contain added campesterol or phytosterol mixtures, particularly under thermal conditions. Heating temperature, heating time, and their interaction are important determinants of POP formation in foods, and the net increase in POP contents is positively associated with heating temperature and duration of heating.

2. Traditional and Historical Use

No traditional or historical use of 5-campestenone as an isolated substance has been identified in the peer-reviewed scientific literature. The compound was not isolated, characterized, or intentionally consumed in any recorded ethnobotanical, Ayurvedic, Traditional Chinese Medicine, or Western herbal tradition prior to its description within modern phytochemistry. Its existence as a discrete phytochemical entity was established in the context of brassinosteroid biosynthesis research and sterol oxidation chemistry in the latter decades of the twentieth century.

The parent compound, campesterol, has a long history of incidental dietary exposure through plant foods consumed across virtually all agricultural cultures — particularly through vegetable oil consumption — but campesterol itself was not intentionally selected or concentrated for medicinal purposes in pre-modern traditions. The recognition that phytosterol-rich diets may support cardiovascular health is a modern nutritional-science observation, not a traditional practice directed at campesterol or its derivatives.

The first published investigation of 5-campestenone as a biologically active dietary compound in animal models appeared in 2002. Suzuki et al. examined the therapeutic effects of dietary exposure to 5-campestenone (24-methylcholest-5-en-3-one), an enone derivative of campesterol, in C57BL/KsJ-db/db mice, which are an animal model of obese type 2 diabetes. Subsequent mechanistic investigations followed in 2005 and 2006 from Japanese research groups, primarily at Tohoku University.

3. Key Constituents and Established Mechanisms of Action

3.1 Chemical Identity as an Active Compound

5-Campestenone is itself the active entity; it is a single defined molecule rather than a mixture. Its core structural features — a Δ5 double bond conjugated with a C-3 ketone (an α,β-unsaturated ketone or enone system) — are believed to underlie its biological activity. This enone motif distinguishes it functionally from the parent alcohol campesterol and from the saturated ketone 5α-campestanone.

3.2 PPARα Activation

The most thoroughly characterized molecular mechanism identified for 5-campestenone is activation of the peroxisome proliferator-activated receptor alpha (PPARα), a nuclear transcription factor that governs fatty acid catabolism and energy expenditure. Campestenone activated human peroxisome proliferator-activated receptor (PPAR) alpha as determined using the novel GAL4 ligand-binding domain chimera assay system with coactivator coexpression. PPARα activation increases the transcription of genes encoding enzymes of mitochondrial and peroxisomal β-oxidation, thereby augmenting cellular capacity to oxidize fatty acids. Dietary campestenone dramatically increased the activities and the mRNA expressions of mitochondrial and peroxisomal enzymes involved in beta-oxidation in the liver.

3.3 Suppression of Fatty Acid Synthesis and SREBP-1

Complementing its pro-oxidative effects, campestenone simultaneously reduces the anabolic arm of fatty acid metabolism. Dietary campestenone reduced the activities and the mRNA expressions of enzymes involved in fatty acid synthesis, except for the malic enzyme. This downregulation is consistent with, and may be partly mediated by, suppression of the master transcriptional regulator of lipogenic genes: dietary campestenone decreased the sterol regulatory element binding protein-1 (SREBP-1) mRNA level.

3.4 Enhancement of Hepatic Fatty Acid Oxidation and Ketogenesis

In a perfused rat liver system, dietary pretreatment with 5-campestenone produced coordinated changes in hepatic lipid flux. Dietary 5-campestenone markedly elevated hepatic ketone body production, while cumulative secretions of TG, cholesterol, and phospholipid by the livers of rats fed 5-campestenone were all significantly lowered as compared to those fed without the compound; the extent of the reduction was more prominent in the secretion of TG than other lipid components. These results suggest that dietary 5-campestenone exerts its hypotriglyceridemic effect, at least in part, through an enhanced metabolism of endogenous and exogenous fatty acids to oxidation at the expense of esterification in rat liver.

3.5 Reduction of Cholesterol Absorption

Dietary campestenone reduced hepatic cholesterol concentration and increased fecal excretion of neutral steroids originating from cholesterol; lymphatic absorption of cholesterol was reduced by the coadministration of campestenone in rats cannulated in the thoracic duct. This suggests that campestenone, consistent with the behavior of other phytosterols, may interfere with intestinal cholesterol absorption, though the precise mechanism has not been fully elucidated in published studies.

3.6 Relationship to Plant 5α-Reductase (DET2) and Mammalian Homologs

An illuminating aspect of 5-campestenone's biochemistry is its role as the natural substrate for the plant enzyme DET2, which is the ortholog of mammalian steroid 5α-reductase. Campestenone, the natural substrate of DET2, is reduced to 5α-campestanone by both human 5α-reductase isozymes but with different affinities. This finding implies that human enzymes can metabolize exogenously administered 5-campestenone via a pathway structurally analogous to the reduction of testosterone to dihydrotestosterone (DHT), although the physiological consequences of this conversion in humans remain uncharacterized. Steroid 5α-reductase 1/2 (SRD5A1/2) is an androgen protein that resembles the plant DET2 and is responsible for the conversion of testosterone to the more active dihydrotestosterone (DHT); both proteins share functional homology and have a common ancestor.

4. Scientific Evidence by Area of Use

Important characterization of evidence quality: As of the available peer-reviewed literature, all published efficacy data on 5-campestenone derive from animal experiments (rodent models) and one in vitro receptor assay. No human clinical trials or randomized controlled trials in humans have been published. All findings below must therefore be understood as preliminary preclinical evidence whose translation to human health outcomes is unestablished.

4.1 Glycemic Control and Type 2 Diabetes Models

The earliest investigation in an animal diabetes model provided the foundational evidence for campestenone's metabolic effects. Suzuki et al. (2002) examined the therapeutic effects of dietary exposure to 5-campestenone in C57BL/KsJ-db/db mice, an animal model of obese type 2 diabetes; blood glucose levels of db/db mice linearly increased from 270 to 720 mg/dL in 10 weeks, and a 0.3% dietary exposure to 5-campestenone caused a marked reduction in blood glucose levels of 330 mg/dL after 10 weeks of feeding, with a concomitant inhibition of glucose excretion in urine. Only slight efficacy was observed with 0.1% dietary exposure in db/db mice; significant decreases of plasma triglyceride and plasma free fatty acid were also observed in db/db mice at the 0.3% dose. A prominent decrease in blood glucose levels with concurrent glucose elimination inhibition in urine was reported in db/db mice fed with 0.3% 5-campestenone after eight weeks.

A subsequent study replicated and extended these observations in a second rodent model. Konno et al. (2005) examined the therapeutic effects of dietary exposure to 5-campestenone (24-methylcholest-5-en-3-one) in Zucker diabetic fatty (ZDF) rats, an animal model of type 2 diabetes mellitus, and dietary 0.6% exposure to 5-campestenone caused marked reductions. Dietary 0.6% exposure to 5-campestenone caused marked reduction in hemoglobin A1c (HbA1c), plasma total cholesterol, triglycerides, and non-esterified fatty acid (NEFA). In particular, plasma triglyceride levels were reduced in the 0.6% 5-campestenone-fed group to about 25% of that in the control group. In the oral glucose tolerance test (OGTT) at three and seven weeks after the beginning of treatment, 5-campestenone limited the rise of blood glucose levels by oral administration of glucose dose-dependently.

Evidence strength: Weak to preliminary. All data are from rodent models of genetically induced obesity/diabetes. No human clinical trials exist. The doses used in animal diets (0.1–0.6% of total diet mass) do not translate directly to standardized human mg/kg dosing without pharmacokinetic studies that have not been published.

4.2 Lipid Metabolism, Hypertriglyceridemia, and Visceral Adiposity

The most extensively studied area in the preclinical literature concerns the effects of dietary 5-campestenone on lipid profiles and fat distribution in rodents. Dietary campest-5-en-3-one (campestenone) significantly reduced visceral fat weight and the concentration of triacylglycerol in serum and liver of rats. Energy expenditure was significantly higher in rats fed campestenone. Dietary campestenone reduced hepatic cholesterol concentration and increased fecal excretion of neutral steroids originated from cholesterol; lymphatic absorption of cholesterol was also reduced by coadministration of campestenone in rats cannulated in the thoracic duct.

In the Zucker diabetic fatty rat model, adipose tissue deposits were also affected beyond simple lipid markers: amounts of adipose tissue in the retroperitoneum and periepididymal area as well as abdominal subcutaneous fat were significantly decreased in animals fed 0.6% 5-campestenone.

The rat liver perfusion model provided mechanistic detail confirming that the effects on serum triglycerides reflect altered hepatic lipid processing. Male Sprague-Dawley rats fed a diet supplemented with 0.2% 5-campestenone for 14 days showed a marked reduction in the concentrations of serum lipids such as triacylglycerol (TG), cholesterol, phospholipid, and free fatty acid, without influencing food intake or growth. The reduction of TG secretion was concomitantly accompanied by the reduced incorporation of both exogenous and endogenous fatty acids into this lipid molecule.

Dietary campestenone contributed to the reduction of body weight gain and visceral fat deposition in rats.

Evidence strength: Weak to preliminary. All data are from acute and subchronic rodent dietary studies. No human interventional data exist. The mechanistic pathway (PPARα activation) is well-characterized at the molecular level, providing biological plausibility, but clinical confirmation is absent.

4.3 Cardiovascular Risk Markers

The documented reductions in serum triacylglycerol and cholesterol in animal models have led investigators to propose a potential cardiovascular relevance of campestenone. Researchers suggest the possibility that campestenone has an ability to prevent coronary heart disease by improving obesity and abnormality of lipid metabolism. Previous work showed that dietary campestenone markedly reduced blood glucose and serum triacylglycerol and cholesterol in mice of a type 2 diabetes model; these observations suggest a possibility that dietary campestenone multi-functionally influences lipid and glucose metabolism and may contribute to preventing coronary heart disease and obesity.

Evidence strength: Speculative. These cardiovascular propositions are extrapolations from surrogate biomarkers (serum lipids) in rodent models. No human cardiovascular endpoint studies have been conducted.

4.4 Natural Occurrence in Botanical Sources (Plant Biochemistry)

While not constituting a health evidence area per se, it is well-documented that 5-campestenone is a natural metabolite present in plants as a brassinosteroid biosynthesis intermediate. GC-qMS analysis of Mimosa caesalpiniifolia stem bark identified campestenone (combined peak with β-amyrin at 8.7% relative abundance) among the chemical constituents. This illustrates that campestenone can be detected as a naturally occurring minor constituent in plant materials where campesterol undergoes oxidative metabolism.

5. Body Systems and Health Areas Associated with 5-Campestenone

• Hepatic / Liver: Dietary 5-campestenone markedly elevated hepatic ketone body production, while cumulative secretions of TG, cholesterol, and phospholipid by the liver were significantly lowered. The liver appears to be the primary site of campestenone's effects on lipid flux, based on all available preclinical data.
• Adipose Tissue / Body Composition: Dietary campestenone significantly reduced visceral fat weight in rats. Amounts of adipose tissue in retroperitoneal, periepididymal, and abdominal subcutaneous depots were significantly decreased in animals fed 0.6% 5-campestenone.
• Cardiovascular / Lipid Metabolism: Reductions in serum triacylglycerols, cholesterol, and free fatty acids have been documented across multiple rodent models. 5-Campestenone feeding resulted in a marked reduction in the concentrations of serum lipids including triacylglycerol, cholesterol, phospholipid, and free fatty acid, without influencing food intake or growth.
• Endocrine / Glucose Homeostasis: Dietary 0.6% exposure to 5-campestenone caused marked reduction in hemoglobin A1c (HbA1c), plasma total cholesterol, triglycerides, and non-esterified fatty acid.
• Energy Metabolism / Mitochondrial Function: Dietary campestenone dramatically increased the activities and the mRNA expressions of mitochondrial and peroxisomal enzymes involved in beta-oxidation in the liver, and campestenone activated human PPARα.
• Steroid Metabolism (Plant Biology and Cross-Species Relevance): Campestenone, the natural substrate of DET2, is reduced to 5α-campestanone by both human 5α-reductase isozymes but with different affinities, indicating biochemical cross-reactivity with human steroid-metabolizing enzymes whose physiological consequences have not been defined.

6. Dosage Forms and Reported Dosages

No human dosage data exist. All reported dosages below derive exclusively from animal dietary supplementation studies. They are expressed as percentage of total diet by weight (w/w), reflecting the experimental protocols used by researchers.

• 0.1% dietary (mouse): Only slight efficacy was observed with 0.1% dietary exposure to 5-campestenone in db/db mice.
• 0.2% dietary (rat, liver perfusion): Male Sprague-Dawley rats were fed a diet supplemented with 0.2% 5-campestenone for 14 days, which resulted in a marked reduction in serum lipid concentrations without influencing food intake or growth.
• 0.3% dietary (mouse, db/db model): The 0.3% dietary exposure to 5-campestenone caused a marked reduction in blood glucose levels to 330 mg/dL after 10 weeks of feeding, with concomitant inhibition of glucose excretion in urine. Significant decreases of plasma triglyceride and plasma free fatty acid were also observed in db/db mice at the 0.3% dose.
• 0.6% dietary (ZDF rat model): Dietary 0.6% exposure to 5-campestenone caused marked reduction in HbA1c, plasma total cholesterol, triglycerides, and NEFA; in particular, plasma triglyceride levels were reduced to about 25% of control group values.

The chemical synthesis protocol used in research contexts starts with highly purified campesterol (>99% purity). Highly purified campesterol (purity >99%) was purchased from commercial sources, and campest-5-en-3-one was chemically synthesized from campesterol according to the method of Parish et al. No standardized formulations, encapsulated supplements, or official pharmacopeial monographs for 5-campestenone as a supplement ingredient have been identified in the literature.

7. Safety Considerations and Known Interactions

7.1 Animal Safety Observations

Gross toxicological assessments in the animal studies available have not revealed obvious adverse effects at the doses tested. No obvious anomaly due to consumption of 5-campestenone was detected by necropsy or clinical observation in the db/db mouse study (0.3% dietary dose, 10 weeks). No obvious anomaly due to consumption of 5-campestenone was detected in necropsy or clinical observations in the ZDF rat study (0.6% dietary dose). In the rat lipid metabolism study, 5-campestenone feeding resulted in a marked reduction in serum lipid concentrations without influencing food intake or growth. These findings provide limited reassurance at the specific doses and durations studied in rodents, but cannot be extrapolated to human safety without dedicated human toxicological data.

7.2 Phytosterol Oxidation Products: Class-Level Safety Concerns

5-Campestenone is a member of the phytosterol oxidation product (POP) chemical class, and the safety of POPs as a class is an active area of concern in the nutritional science literature. An increasing amount of research shows that POPs have biological effects different from their corresponding parent phytosterols; reported biological effects include modulating lipid and glucose metabolism, cell apoptosis, inflammation processes, and immune reactions, which may be linked to either beneficial effects (e.g., anti-diabetic and anti-tumour) or detrimental effects (e.g., atherogenicity, cytotoxicity, pro-inflammation, mitochondrial dysfunction, glutathione depletion, and oxidative stress). A main health concern is the speculation that POPs, like cholesterol oxidation products, may be more atherogenic than cholesterol because of their molecular structure similarity; cholesterol oxidation products have been shown to contribute to the pathological processes of atherosclerosis.

However, researchers have noted important caveats regarding in vitro cytotoxicity data. Although it has been suggested that some oxidation products are cytotoxic, atherogenic, mutagenic, and carcinogenic, these conclusions have been mainly drawn from in vitro experiments with pure sterol oxides, which is not representative of the in vivo situation where sterol oxides are normally only found in trace amounts in the presence of a large excess of cholesterol.

7.3 Cytotoxicity of Campesterol Oxidation Products

Studies examining campesterol-derived oxidation products in cell culture systems have identified cytotoxic potential. Phytosterols contain an unsaturated ring structure and therefore are susceptible to oxidation under certain conditions; whilst the cytotoxicity of the analogous cholesterol oxidation products has been well documented, the biological effects of phytosterol oxidation products have not yet been fully ascertained. More specifically with respect to campesterol-derived POPs, in vitro data suggest cytotoxicity in human cell lines, though these findings are from cell culture models and their relevance to oral dietary exposure in vivo has not been established.

7.4 Interaction with Human Steroid-Metabolizing Enzymes

As noted in the mechanistic section, 5-campestenone is a substrate for human 5α-reductase enzymes. Campestenone, the natural substrate of DET2, is reduced to 5α-campestanone by both human 5α-reductase isozymes but with different affinities. The implications of this for endogenous steroid hormone balance — particularly androgens, given that 5α-reductase converts testosterone to DHT — have not been investigated in published human studies. This represents an uncharacterized potential interaction that warrants attention in future research.

7.5 Effects on Dietary Fat-Soluble Vitamin Absorption

This concern is established for parent phytosterols generally, not specifically for 5-campestenone. Randomized trials have shown that plant sterols and stanols lower blood concentrations of β-carotene by about 25%, concentrations of α-carotene by 10%, and concentrations of vitamin E by 8%. Whether campestenone, as a structurally related but oxidized derivative, exerts similar effects on fat-soluble vitamin absorption has not been studied.

7.6 Absence of Human Clinical Evidence

A critical safety limitation is the complete absence of human trial data. An oxycampesterol (campestenone) has been found to reduce body weight gain, visceral fat deposition, serum triacylglycerols, and blood glucose in mice and rats; however, these hypotheses need to be further studied in humans. Without pharmacokinetic data on absorption, distribution, metabolism, and excretion (ADME) in humans, safe dosage ranges, potential drug interactions, and contraindications cannot be defined from the existing literature.

Summary of Evidence Quality

The published scientific record on 5-campestenone consists of a small number of peer-reviewed animal studies (primarily from one Japanese research group at Tohoku University, published 2002–2006), one in vitro receptor activation assay, and broader class-level data on phytosterol oxidation products. The compound has no recognized traditional history of intentional use, no approved status as a pharmaceutical or regulated dietary supplement ingredient in major jurisdictions based on available sources, no human clinical trials, and no pharmacopeial monograph. Its biochemistry within the brassinosteroid biosynthesis pathway is well characterized at the molecular level. All proposed human health benefits — including anti-diabetic, anti-obesity, and hypolipidemic effects — remain at the preliminary preclinical stage and cannot currently be substantiated as established human health claims.

References

• Suzuki K, Tanaka M, Konno R, Kaneko Y. Effects of 5-campestenone (24-methylcholest-5-en-3-one) on the type 2 diabetes mellitus model animal C57BL/KsJ-db/db mice. Horm Metab Res. 2002;34(3):121–126. PubMed PMID: 11972300.
• Konno R, Kaneko Y, Suzuki K, Matsui Y. Effect of 5-Campestenone (24-methylcholest-5-en-3-one) on Zucker diabetic fatty rats as a type 2 diabetes mellitus model. Horm Metab Res. 2005;37(2):79–83. Thieme Connect.
• Ikeda I et al. Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARalpha, promotes energy consumption and reduces visceral fat deposition in rats. Biochim Biophys Acta. 2006;1760(5):800–807. PubMed PMID: 16616424.
• Tamaru S, Suzuki Y, Sakono M, Fukuda N, Ikeda I, Konno R, Shimizu T, Suzuki K. Dietary 5-Campestenone (Campest-5-en-3-one) Enhances Fatty Acid Oxidation in Perfused Rat Liver. J Nutr Sci Vitaminol. 2006;52(2):127–133. J-STAGE.
• Rosati F et al. New evidence of similarity between human and plant steroid metabolism: 5alpha-reductase activity in Solanum malacoxylon. J Steroid Biochem Mol Biol. 2003;84(2–3):205–209. PubMed PMID: 12488348.
• Sakono M et al. The Cholesterol Metabolite Cholest-5-en-3-One Alleviates Hyperglycemia and Hyperinsulinemia in Obese (db/db) Mice. Metabolites. 2022;12(1):26. PMC8779233.
• Lin Y et al. Phytosterol oxidation products (POP) in foods with added phytosterols and estimation of their daily intake: A literature review. Eur J Lipid Sci Technol. 2016;118(9):1286–1295. PMC5066650.
• Ryan E, Chopra J, McCarthy F, Maguire AR, O'Brien NM. Qualitative and quantitative comparison of the cytotoxic and apoptotic potential of phytosterol oxidation products with their corresponding cholesterol oxidation products. Br J Nutr. 2005;94(3):443–451. Cambridge Core.
• Slesinski RS et al. Safety evaluation of phytosterol esters. Part 8. Lack of genotoxicity and subchronic toxicity with phytosterol oxides. Food Chem Toxicol. 2005;43(4):609–618. ScienceDirect.
• Nomura T et al. Brassinosteroid/Sterol Synthesis and Plant Growth as Affected by lka and lkb Mutations of Pea. Plant Physiol. 2001;127(2):576–588. PMC32037.
• Clouse SD. Brassinosteroids. Arabidopsis Book. 2011;9:e0151. PMC3243304.
• Marcelino G et al. Phytosterols: From Preclinical Evidence to Potential Clinical Applications. Front Pharmacol. 2020;11:599959. Frontiers.
• Costa LS et al. Assessing Chemical Constituents of Mimosa caesalpiniifolia Stem Bark: Possible Bioactive Components Accountable for the Cytotoxic Effect on Human Tumour Cell Lines. Molecules. 2018;23(12):3187. PMC6272184.
• Wikipedia. Campesterol. (For natural source data on campesterol distribution in foods.)